Page3
Bryant A, et al. Am J Ther. 2021 Aug 27;28(5):e573-e576. doi: 10.1097/MJT.0000000000001442. Am J Ther. 2021. PMID: 34469921
. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, Piruzeli MLB, Goldman JD, Alatorre-Alexander J, de Cassia Pellegrini R, Estrada V, Som M, Cardoso A, Chakladar S, Crowe B, Reis P, Zhang X, Adams DH, Ely EW; COV-BARRIER Study Group.
.
Impact of the Delta variant on vaccine efficacy and response strategies.
Bian L, Gao Q, Gao F, Wang Q, He Q, Wu X, Mao Q, Xu M, Liang Z. Bian L, et al.
.
Health and Clinical Management.
Monga B. Monga B. Yearb Med Inform. 2004;(1):269-271.
![top](data:image/svg+xml,%3Csvg%20xmlns="http://www.w3.org/2000/svg"%20width="16"%20height="16"%3E%3Crect%20fill-opacity="0"/%3E%3C/svg%3E "top")
